Φορτώνει......
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM)...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | EMBO Mol Med |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley and Sons Inc.
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7005646/ https://ncbi.nlm.nih.gov/pubmed/31930715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201809910 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|